ATLANTA, GEORGIA—A “third generation” tyrosine kinase inhibitor — ponatinib — has succeeded in controlling chronic myeloid leukaemia and Philadelphia-positive acute lymphoblastic leukaemia
ATLANTA, GEORGIA—A “third generation” tyrosine kinase inhibitor — ponatinib — has succeeded in controlling chronic myeloid leukaemia and Philadelphia-positive acute lymphoblastic leukaemia in patients who have the feared T 315 I mutation — which has prevented imatinib and “second generation” TKIs nilotinib and dasatinib from suppressing the disease. At the American Society of Hematology annual meeting Dr Jorge Cortes from the MD Anderson Cancer Center in Houston, Texas, reported findings from a “pivotal phase II trial” which, he explained to Peter Goodwin, mark a significant step forwards towards relegating these malignancies to the status of manageable diseases.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/121219JorgeCortesPODCASTLoRes.mp3]